Pharmaceutical Sales Certification (PSC) &
CNPR Exam Practice Questions Complete
Study Guide with Verified Answers & Detailed
Rationales 2026
2026/2027 Edition | National Association of Pharmaceutical
Sales Representatives (NAPSRx)
1. A pharmaceutical sales representative is preparing a presentation
for a formulary review committee. The drug has demonstrated
superiority in a head-to-head trial, but the primary endpoint was a
secondary outcome in the original trial design. Which of the following
statements is most appropriate and compliant with FDA regulations
regarding the presentation of clinical data?
• A) "Our drug is superior to the competitor based on the head-to-
head trial results."
• B) "The head-to-head trial showed a statistically significant
difference in the secondary endpoint, which was analyzed as part
of the trial design."
• C) "We can discuss the superiority of our drug because it was a
secondary endpoint."
• D) "The superiority finding is valid because it was a pre-specified
analysis."
Rationale: Secondary endpoints, even when pre-specified, must be presented
with appropriate context to avoid misleading claims about superiority. The
FDA requires that promotional materials not overstate findings or
,misrepresent the strength of evidence from clinical trials. Presenting the data
accurately with the endpoint classification is the most compliant approach.
2. A pharmaceutical sales representative is discussing a new
medication with a physician who has a large Medicare patient
population. The physician is concerned about the drug being placed
on Medicare Part D's "protected class" list. Which of the following
statements accurately describes why certain drug classes receive this
designation?
• A) Protected classes are only for drugs with generic alternatives
available.
• B) Protected classes include drugs used to treat serious conditions
like cancer, HIV, and immunosuppressants, and require Medicare
plans to cover them.
• C) Protected class designation means the drug is automatically
covered without prior authorization.
• D) Protected class status is granted to all new medications upon FDA
approval.
Rationale: Medicare Part D requires that plans cover all drugs in six protected
classes: antidepressants, antipsychotics, anticonvulsants,
immunosuppressants, antiretrovirals, and antineoplastics. This ensures that
patients with serious conditions have consistent access to necessary
medications. The designation applies to the class, not to individual drugs, and
coverage may still be subject to utilization management.
3. A pharmaceutical representative is calling on a physician who is a
key opinion leader (KOL). The physician expresses interest in
participating in a speaker's bureau for the representative's drug.
,Which of the following is the most appropriate action for the
representative to take in compliance with the PhRMA Code?
• A) Ensure that the physician has genuine expertise and that the
speaking engagement is a legitimate educational activity with an
honorarium that reflects fair market value.
• B) Offer the physician a substantial honorarium regardless of
expertise to secure participation.
• C) Select the physician based on prescribing potential rather than
expertise.
• D) Provide the physician with talking points prepared by the
marketing department.
Rationale: The PhRMA Code requires that speaker arrangements be based on
legitimate expertise and that compensation be fair market value. Speakers
should have genuine knowledge and experience, and the content should be
educational. Compensation should be for actual services and not tied to
prescribing behavior.
4. A pharmaceutical sales representative is preparing a call on a
urologist to discuss a new medication for overactive bladder. The
representative knows the drug has an anticholinergic mechanism of
action. Which patient population should the representative mention as
being at higher risk for anticholinergic side effects?
• A) Young adults and adolescents
• B) Patients with hypertension
• C) Older adults, especially those with cognitive impairment
• D) Patients with diabetes
Rationale: Older adults are particularly sensitive to anticholinergic side
effects, including confusion, cognitive decline, constipation, and urinary
retention. These effects can be exacerbated in patients with pre-existing
, cognitive impairment. The representative should discuss this risk
appropriately as part of fair balance.
5. A representative is analyzing the competitive landscape for a new
oral anticoagulant. The representative's drug is a direct oral
anticoagulant (DOAC) that is more expensive than warfarin but offers
dosing convenience and fewer dietary restrictions. Which of the
following is the most compelling argument for formulary inclusion?
• A) The drug is more expensive but patients prefer it.
• B) The drug does not require routine INR monitoring, which reduces
healthcare utilization costs.
• C) The drug is newer and therefore better.
• D) The drug offers predictable pharmacokinetics, no dietary
restrictions, and reduced monitoring requirements that may
offset the higher drug cost.
Rationale: The total cost of care argument is the most compelling for
formulary decisions. While DOACs are more expensive than warfarin, the
reduced monitoring costs, no dietary restrictions, and predictable
pharmacokinetics can offset the higher drug cost. This "value proposition" is
the most appropriate to present to a P&T committee.
6. A pharmaceutical sales representative is discussing a new
medication for chronic migraine prevention with a neurologist. The
physician asks about the drug's effect on quality of life. Which of the
following is the most appropriate response?
• A) "Quality of life was not measured in the clinical trials."
CNPR Exam Practice Questions Complete
Study Guide with Verified Answers & Detailed
Rationales 2026
2026/2027 Edition | National Association of Pharmaceutical
Sales Representatives (NAPSRx)
1. A pharmaceutical sales representative is preparing a presentation
for a formulary review committee. The drug has demonstrated
superiority in a head-to-head trial, but the primary endpoint was a
secondary outcome in the original trial design. Which of the following
statements is most appropriate and compliant with FDA regulations
regarding the presentation of clinical data?
• A) "Our drug is superior to the competitor based on the head-to-
head trial results."
• B) "The head-to-head trial showed a statistically significant
difference in the secondary endpoint, which was analyzed as part
of the trial design."
• C) "We can discuss the superiority of our drug because it was a
secondary endpoint."
• D) "The superiority finding is valid because it was a pre-specified
analysis."
Rationale: Secondary endpoints, even when pre-specified, must be presented
with appropriate context to avoid misleading claims about superiority. The
FDA requires that promotional materials not overstate findings or
,misrepresent the strength of evidence from clinical trials. Presenting the data
accurately with the endpoint classification is the most compliant approach.
2. A pharmaceutical sales representative is discussing a new
medication with a physician who has a large Medicare patient
population. The physician is concerned about the drug being placed
on Medicare Part D's "protected class" list. Which of the following
statements accurately describes why certain drug classes receive this
designation?
• A) Protected classes are only for drugs with generic alternatives
available.
• B) Protected classes include drugs used to treat serious conditions
like cancer, HIV, and immunosuppressants, and require Medicare
plans to cover them.
• C) Protected class designation means the drug is automatically
covered without prior authorization.
• D) Protected class status is granted to all new medications upon FDA
approval.
Rationale: Medicare Part D requires that plans cover all drugs in six protected
classes: antidepressants, antipsychotics, anticonvulsants,
immunosuppressants, antiretrovirals, and antineoplastics. This ensures that
patients with serious conditions have consistent access to necessary
medications. The designation applies to the class, not to individual drugs, and
coverage may still be subject to utilization management.
3. A pharmaceutical representative is calling on a physician who is a
key opinion leader (KOL). The physician expresses interest in
participating in a speaker's bureau for the representative's drug.
,Which of the following is the most appropriate action for the
representative to take in compliance with the PhRMA Code?
• A) Ensure that the physician has genuine expertise and that the
speaking engagement is a legitimate educational activity with an
honorarium that reflects fair market value.
• B) Offer the physician a substantial honorarium regardless of
expertise to secure participation.
• C) Select the physician based on prescribing potential rather than
expertise.
• D) Provide the physician with talking points prepared by the
marketing department.
Rationale: The PhRMA Code requires that speaker arrangements be based on
legitimate expertise and that compensation be fair market value. Speakers
should have genuine knowledge and experience, and the content should be
educational. Compensation should be for actual services and not tied to
prescribing behavior.
4. A pharmaceutical sales representative is preparing a call on a
urologist to discuss a new medication for overactive bladder. The
representative knows the drug has an anticholinergic mechanism of
action. Which patient population should the representative mention as
being at higher risk for anticholinergic side effects?
• A) Young adults and adolescents
• B) Patients with hypertension
• C) Older adults, especially those with cognitive impairment
• D) Patients with diabetes
Rationale: Older adults are particularly sensitive to anticholinergic side
effects, including confusion, cognitive decline, constipation, and urinary
retention. These effects can be exacerbated in patients with pre-existing
, cognitive impairment. The representative should discuss this risk
appropriately as part of fair balance.
5. A representative is analyzing the competitive landscape for a new
oral anticoagulant. The representative's drug is a direct oral
anticoagulant (DOAC) that is more expensive than warfarin but offers
dosing convenience and fewer dietary restrictions. Which of the
following is the most compelling argument for formulary inclusion?
• A) The drug is more expensive but patients prefer it.
• B) The drug does not require routine INR monitoring, which reduces
healthcare utilization costs.
• C) The drug is newer and therefore better.
• D) The drug offers predictable pharmacokinetics, no dietary
restrictions, and reduced monitoring requirements that may
offset the higher drug cost.
Rationale: The total cost of care argument is the most compelling for
formulary decisions. While DOACs are more expensive than warfarin, the
reduced monitoring costs, no dietary restrictions, and predictable
pharmacokinetics can offset the higher drug cost. This "value proposition" is
the most appropriate to present to a P&T committee.
6. A pharmaceutical sales representative is discussing a new
medication for chronic migraine prevention with a neurologist. The
physician asks about the drug's effect on quality of life. Which of the
following is the most appropriate response?
• A) "Quality of life was not measured in the clinical trials."
